

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SciClone Pharmaceuticals (Holdings) Limited

賽生藥業控股有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6600)

DATE OF BOARD MEETING

The board of directors (the “**Board**”) of SciClone Pharmaceuticals (Holdings) Limited (the “**Company**”, and its subsidiaries, the “**Group**”) hereby announces that a meeting of the Board will be held on Thursday, March 28, 2024 for the purpose of, among other matters, considering and approving the final results of the Group for the year ended December 31, 2023, and recommendation of a final dividend, if any, and transacting any other business.

By Order of the Board

SciClone Pharmaceuticals (Holdings) Limited

Pan Rongrong

*Executive Director, Chief Financial Officer and
Joint Company Secretary*

Hong Kong, March 18, 2024

As at the date of this announcement, the Board comprises Mr. Zhao Hong and Ms. Pan Rongrong as executive directors, Mr. Li Zhenfu, Dr. Daniel Luzius Vasella, Ms. Lin Shirley Yi-Hsien and Ms. Wang Haixia as non-executive directors, and Dr. Liu Guoen, Dr. Chen Ping, Mr. Gu Alex Yushao and Ms. Wendy Hayes as independent non-executive directors.

* *For identification purpose only*